A combination treatment of anti‐CTLA‐4 antibodies and anti‐PD‐1 antibodies with small molecule cabozantinib or BEZ235 to clear MDSCs has exhibited a good therapeutic effect on PCa in animal models.[38] However, cabozantinib and BEZ235 are multi‐kinase inhibitors that not only target MDSCs but also have broad effects on various cells.[39] Our work shows that anti‐IL‐1β antibody exert a significant suppression of MDSCs infiltration. The gene discussed is CTLA4; the disease is posterior cortical atrophy.